Patient Preferences for Long-Term Prophylactic Treatment in Hereditary Angioedema: A Discrete-Choice Experiment
A reduction in attack frequency is the most important treatment feature for adults living with hereditary angioedema. The heterogeneity in patient perspectives highlights the need for patient-physician communication when making decisions about initiating a new long-term prophylactic treatment for hereditary angioedema.
Authors
- Carol Mansfield (ORCID: https://orcid.org/0000-0002-3144-8938)
- Kathleen F. Villa
- Caroline Vass
- James A. Ruggles
- Laura Bordone
- Aaron Yarlas
- Cannon Kent
Institutions
- Ionis Pharmaceuticals (United States) (US)
- RTI Health Solutions (US)
Publication Details
- Journal
- Patient
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1007/s40271-025-00798-8
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ionis Pharmaceuticals